Top

Published in:

01-08-2020 | Heart Failure | Comorbidities (T von Lueder & I Hopper, Section Editors)

Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction

Authors: Andrew Xanthopoulos, Apostolos Dimos, Grigorios Giamouzis, Angeliki Bourazana, Alexandros Zagouras, Michail Papamichalis, Takeshi Kitai, John Skoularigis, Filippos Triposkiadis

Published in: Current Heart Failure Reports | Issue 4/2020

Abstract

Purpose of Review

Heart failure (HF) patients often present with multiple coexisting morbidities. In this review, we contend that coexisting morbidities are highly prevalent and clinically important regardless of the left ventricular ejection fraction (LVEF).

Recent Findings

Multimorbidity is prevalent in the ambulatory subjects of the community and increases with age. Differences in the prevalence of coexisting morbidities between HF with preserved LVEF (> 50%), mid-range LVEF (40–50%), and reduced LVEF (< 40%) are either not demonstrable or whenever present are small and unrelated to morbidity and mortality. The constellation of coexisting morbidities together with the disease modifiers (age, sex, genes, other) defines the HF phenotype and outcome.

Summary

There is no robust evidence supporting an interaction in HF patients between the prevalence and clinical significance of coexisting morbidities and the LVEF.

Khan HTA. Population ageing in a globalized world: risks and dilemmas? J Eval Clin Pract. 2019;25(5):754–60. https://doi.org/10.1111/jep.13071.CrossRefPubMed

Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596. https://doi.org/10.1161/CIR.0000000000000757.CrossRefPubMed

Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail. 2016;18(7):744–58. https://doi.org/10.1002/ejhf.600.CrossRefPubMed

Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71. https://doi.org/10.1016/j.jacc.2013.02.092.CrossRefPubMed

•• Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J. 2019;40(26):2155–63. https://doi.org/10.1093/eurheartj/ehz158. The authors propose that heart failure is a spectrum of phenotypes with overlapping and distinct characteristics.CrossRefPubMed

Rocca WA, Boyd CM, Grossardt BR, Bobo WV, Finney Rutten LJ, Roger VL, et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. Mayo Clin Proc. 2014;89(10):1336–49. https://doi.org/10.1016/j.mayocp.2014.07.010.CrossRefPubMedPubMedCentral

Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43. https://doi.org/10.1016/S0140-6736(12)60240-2.CrossRef

Willadsen TG, Siersma V, Nicolaisdottir DR, Koster-Rasmussen R, Jarbol DE, Reventlow S, et al. Multimorbidity and mortality: A 15-year longitudinal registry-based nationwide Danish population study. J Comorb. 2018;8(1):2235042X18804063. https://doi.org/10.1177/2235042X18804063.CrossRefPubMedPubMedCentral

Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124(2):136–43. https://doi.org/10.1016/j.amjmed.2010.08.017.CrossRefPubMedPubMedCentral

10.

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–80. https://doi.org/10.1016/S0140-6736(17)32520-5.CrossRefPubMedPubMedCentral

11.

Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65–75. https://doi.org/10.1161/CIRCULATIONAHA.111.080770.CrossRefPubMed

12.

van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16(1):103–11. https://doi.org/10.1002/ejhf.30.CrossRefPubMed

13.

Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574–85. https://doi.org/10.1002/ejhf.813.CrossRefPubMed

14.

•• Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132–9. https://doi.org/10.1016/j.ijcard.2018.04.001. This study showed that the higher prevalence of morbidities in heart failure with preserved left ventricular ejection fraction vs reduced left ventricular ejection fraction doesn’t necessarily translate into a worse outcome.CrossRefPubMed

15.

Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail. 2018;20(9):1257–66. https://doi.org/10.1002/ejhf.1202.CrossRefPubMed

16.

Ergatoudes C, Schaufelberger M, Andersson B, Pivodic A, Dahlstrom U, Fu M. Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry. Clin Res Cardiol. 2019;108(9):1025–33. https://doi.org/10.1007/s00392-019-01430-0.CrossRefPubMedPubMedCentral

17.

Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–93. https://doi.org/10.1016/j.jacc.2014.08.036.CrossRefPubMedPubMedCentral

18.

Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):93–102. https://doi.org/10.1016/j.jchf.2013.01.006.CrossRefPubMed

19.

Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13. https://doi.org/10.1056/NEJMoa020245.CrossRefPubMed

20.

Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614–31. https://doi.org/10.1161/CIRCULATIONAHA.117.032474.CrossRefPubMed

21.

Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–32. https://doi.org/10.1016/j.jacc.2008.12.068.CrossRefPubMed

22.

• Xanthopoulos A, Triposkiadis F, Starling RC. Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. Trends Cardiovasc Med. 2018;28(6):392–400. https://doi.org/10.1016/j.tcm.2018.01.001. This review article highlights the importance of hypertension in the development of heart failure with preserved left ventricular ejection fraction.CrossRefPubMed

23.

Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72. https://doi.org/10.1161/01.cir.0000039105.49749.6f.CrossRefPubMed

24.

Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.CrossRef

25.

Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 2017;5(8):543–51. https://doi.org/10.1016/j.jchf.2017.04.012.CrossRefPubMed

26.

Oh GC, Cho HJ. Blood pressure and heart failure. Clin Hypertens. 2020;26:1. https://doi.org/10.1186/s40885-019-0132-x.CrossRefPubMedPubMedCentral

27.

Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009;95(1):56–62. https://doi.org/10.1136/hrt.2007.134973.CrossRefPubMed

28.

Lee SE, Lee HY, Cho HJ, Choe WS, Kim H, Choi JO, et al. Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure. JACC Heart Fail. 2017;5(11):810–9. https://doi.org/10.1016/j.jchf.2017.08.015.CrossRefPubMed

29.

Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. https://doi.org/10.1016/0002-9149(74)90089-7.CrossRefPubMed

30.

Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38. https://doi.org/10.1161/CIRCRESAHA.117.311586.CrossRefPubMedPubMedCentral

31.

•• Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69–84. https://doi.org/10.1016/j.jacc.2017.11.011. This paper discusses the pathophysiological links between adiposity related risk factors and heart failure development.CrossRefPubMed

32.

•• Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121–41. https://doi.org/10.1161/CIRCRESAHA.118.311371. This review discusses the the impact of existing antihyperglycemic therapies on heart failure.CrossRefPubMedPubMedCentral

33.

Guglin M, Villafranca A, Morrison A. Cardiogenic diabetes. Heart Fail Rev. 2014;19(5):595–602. https://doi.org/10.1007/s10741-013-9412-9.CrossRefPubMed

34.

Ahmad FS, Ning H, Rich JD, Yancy CW, Lloyd-Jones DM, Wilkins JT. Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart Fail. 2016;4(12):911–9. https://doi.org/10.1016/j.jchf.2016.08.001.CrossRefPubMedPubMedCentral

35.

Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114(11):1202–13. https://doi.org/10.1161/CIRCULATIONAHA.106.623199.CrossRefPubMed

36.

Lala A, Desai AS. The role of coronary artery disease in heart failure. Heart Fail Clin. 2014;10(2):353–65. https://doi.org/10.1016/j.hfc.2013.10.002.CrossRefPubMed

37.

Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: mechanisms, incidence and identification of patients at risk. World J Cardiol. 2017;9(5):407–15. https://doi.org/10.4330/wjc.v9.i5.407.CrossRefPubMedPubMedCentral

38.

Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. JACC Heart Fail. 2018;6(3):179–86. https://doi.org/10.1016/j.jchf.2017.09.015.CrossRefPubMed

39.

Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? Cardiol Clin. 2007;25(4):487–95; v. https://doi.org/10.1016/j.ccl.2007.08.010.CrossRefPubMedPubMedCentral

40.

• Braga JR, Austin PC, Ross HJ, Tu JV, Lee DS. Importance of nonobstructive coronary artery disease in the prognosis of patients with heart failure. JACC Heart Fail. 2019;7(6):493–501. https://doi.org/10.1016/j.jchf.2019.02.014. The authors report the prognostic importance of non-obstructive coronary artery disease in heart failure patients.CrossRefPubMed

41.

Triposkiadis F, Pieske B, Butler J, Parissis J, Giamouzis G, Skoularigis J, et al. Global left atrial failure in heart failure. Eur J Heart Fail. 2016;18(11):1307–20. https://doi.org/10.1002/ejhf.645.CrossRefPubMed

42.

Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4.CrossRef

43.

Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128(10):1085–93. https://doi.org/10.1161/CIRCULATIONAHA.113.001475.CrossRefPubMedPubMedCentral

44.

Sartipy U, Dahlstrom U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5(8):565–74. https://doi.org/10.1016/j.jchf.2017.05.001.CrossRefPubMed

45.

Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013;34(36):2795–803. https://doi.org/10.1093/eurheartj/eht192.CrossRefPubMed

46.

Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–9. https://doi.org/10.1093/eurjhf/hfn013.CrossRefPubMedPubMedCentral

47.

Xanthopoulos A, Butler J, Parissis J, Polyzogopoulou E, Skoularigis J, Triposkiadis F. Acutely decompensated versus acute heart failure: two different entities. Heart Fail Rev. 2019. https://doi.org/10.1007/s10741-019-09894-y.

48.

• Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L, et al. Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease. JACC Heart Fail. 2019;7(10):823–33. https://doi.org/10.1016/j.jchf.2019.05.009. This work highlights the differences observed in life-saving therapies between heart failure patients with and without chronic obstructive pulmonary disease.CrossRefPubMed

49.

Canepa M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, Pinilla JMG, Nyolczas N, et al. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20(1):100–10. https://doi.org/10.1002/ejhf.964.CrossRefPubMed

50.

van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8(9):485–93. https://doi.org/10.1038/nrcardio.2011.77.CrossRefPubMed

51.

Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107(5):1747–50. https://doi.org/10.1182/blood-2005-07-3046.CrossRefPubMedPubMedCentral

52.

Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in heart failure: still relevant? JACC Heart Fail. 2018;6(3):201–8. https://doi.org/10.1016/j.jchf.2017.08.023.CrossRefPubMed

53.

Le Jemtel TH, Arain S. Mediators of anemia in chronic heart failure. Heart Fail Clin. 2010;6(3):289–93. https://doi.org/10.1016/j.hfc.2010.03.008.CrossRefPubMed

54.

Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52(7):501–11. https://doi.org/10.1016/j.jacc.2008.04.044.CrossRefPubMed

55.

Rocha BML, Cunha GJL, Menezes Falcao LF. The burden of Iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018;71(7):782–93. https://doi.org/10.1016/j.jacc.2017.12.027.CrossRefPubMed

56.

Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34(11):816–29. https://doi.org/10.1093/eurheartj/ehs224.CrossRefPubMed

57.

Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80–98. https://doi.org/10.1161/CIRCULATIONAHA.118.030099.CrossRefPubMed

58.

Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17(11):899–906. https://doi.org/10.1016/j.cardfail.2011.08.003.CrossRefPubMed

59.

van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–83. https://doi.org/10.1161/CIRCULATIONAHA.117.027497.CrossRefPubMedPubMedCentral

60.

Wienbergen H, Pfister O, Hochadel M, Fach A, Backhaus T, Bruder O, et al. Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clin Res Cardiol. 2019;108(1):93–100. https://doi.org/10.1007/s00392-018-1327-y.CrossRefPubMed

61.

Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–69. https://doi.org/10.1093/eurheartj/eht386.CrossRefPubMed

62.

Lawson CA, Testani JM, Mamas M, Damman K, Jones PW, Teece L, et al. Chronic kidney disease, worsening renal function and outcomes in a heart failure community setting: a UK national study. Int J Cardiol. 2018;267:120–7. https://doi.org/10.1016/j.ijcard.2018.04.090.CrossRefPubMedPubMedCentral

63.

Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36(23):1437–44. https://doi.org/10.1093/eurheartj/ehv010.CrossRefPubMedPubMedCentral

64.

Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry. 2018;26(4):175–84. https://doi.org/10.1097/HRP.0000000000000162.CrossRefPubMedPubMedCentral

65.

Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527–37. https://doi.org/10.1016/j.jacc.2006.06.055.CrossRefPubMed

66.

Mbakwem A, Aina F, Amadi C. Expert opinion-depression in patients with heart failure: is enough being done? Card Fail Rev. 2016;2(2):110–2. https://doi.org/10.15420/cfr.2016:21:1.CrossRefPubMedPubMedCentral

67.

•• Triposkiadis F, Xanthopoulos A, Butler J. Cardiovascular aging and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2019;74(6):804–13. https://doi.org/10.1016/j.jacc.2019.06.053. This review discusses the mechanisms of aging and the potential links with heart failure.CrossRefPubMed

68.

Jang JY, Blum A, Liu J, Finkel T. The role of mitochondria in aging. J Clin Invest. 2018;128(9):3662–70. https://doi.org/10.1172/JCI120842.CrossRefPubMedPubMedCentral

69.

Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, et al. Source of chronic inflammation in aging. Front Cardiovasc Med. 2018;5:12. https://doi.org/10.3389/fcvm.2018.00012.CrossRefPubMedPubMedCentral

70.

Lazar E, Sadek HA, Bergmann O. Cardiomyocyte renewal in the human heart: insights from the fall-out. Eur Heart J. 2017;38(30):2333–42. https://doi.org/10.1093/eurheartj/ehx343.CrossRefPubMedPubMedCentral

71.

Cuomo F, Roccabianca S, Dillon-Murphy D, Xiao N, Humphrey JD, Figueroa CA. Effects of age-associated regional changes in aortic stiffness on human hemodynamics revealed by computational modeling. PLoS One. 2017;12(3):e0173177. https://doi.org/10.1371/journal.pone.0173177.CrossRefPubMedPubMedCentral

72.

Horn MA, Trafford AW. Aging and the cardiac collagen matrix: novel mediators of fibrotic remodelling. J Mol Cell Cardiol. 2016;93:175–85. https://doi.org/10.1016/j.yjmcc.2015.11.005.CrossRefPubMedPubMedCentral

73.

Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–9. https://doi.org/10.1080/07853890701842988.CrossRefPubMed

74.

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94. https://doi.org/10.1093/eurheartj/ehv338.CrossRefPubMed

75.

Dewan P, Rorth R, Jhund PS, Shen L, Raparelli V, Petrie MC, et al. Differential impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol. 2019;73(1):29–40. https://doi.org/10.1016/j.jacc.2018.09.081.CrossRefPubMed

76.

Faxen UL, Hage C, Donal E, Daubert JC, Linde C, Lund LH. Patient reported outcome in HFpEF: sex-specific differences in quality of life and association with outcome. Int J Cardiol. 2018;267:128–32. https://doi.org/10.1016/j.ijcard.2018.04.102.CrossRefPubMed

77.

•• Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM, et al. Sex differences in heart failure. Eur Heart J. 2019;40(47):3859–68c. https://doi.org/10.1093/eurheartj/ehz835. This review discusses the often unrecognized but important sex differences in heart failure patients.CrossRefPubMed

78.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20. https://doi.org/10.1056/NEJMoa1908655.CrossRefPubMed

79.

Eaton CB, Pettinger M, Rossouw J, Martin LW, Foraker R, Quddus A, et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail. 2016;9(10). https://doi.org/10.1161/CIRCHEARTFAILURE.115.002883.

80.

Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail. 2018;6(8):701–9. https://doi.org/10.1016/j.jchf.2018.05.018.CrossRefPubMedPubMedCentral

81.

Toedebusch R, Belenchia A, Pulakat L. Diabetic cardiomyopathy: impact of biological sex on disease development and molecular signatures. Front Physiol. 2018;9:453. https://doi.org/10.3389/fphys.2018.00453.CrossRefPubMedPubMedCentral

82.

Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol. 2010;55(4):283–93. https://doi.org/10.1016/j.jacc.2009.07.029.CrossRefPubMedPubMedCentral

83.

• Beale AL, Meyer P, Marwick TH, Lam CSP, Kaye DM. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation. 2018;138(2):198–205. https://doi.org/10.1161/CIRCULATIONAHA.118.034271. This paper explains the predisosition of women to heart failure with preserved left ventricular ejection fraction, from the pathophysiological point of view.CrossRefPubMed

84.

Anthony J, Sliwa K. Decompensated heart failure in pregnancy. Card Fail Rev. 2016;2(1):20–6. https://doi.org/10.15420/cfr.2015:24:2.CrossRefPubMedPubMedCentral

85.

Keskin M, Avsar S, Hayiroglu MI, Keskin T, Borklu EB, Kaya A, et al. Relation of the number of parity to left ventricular diastolic function in pregnancy. Am J Cardiol. 2017;120(1):154–9. https://doi.org/10.1016/j.amjcard.2017.03.244.CrossRefPubMed

86.

Orabona R, Sciatti E, Prefumo F, Vizzardi E, Bonadei I, Valcamonico A, et al. Pre-eclampsia and heart failure: a close relationship. Ultrasound Obstet Gynecol. 2018;52(3):297–301. https://doi.org/10.1002/uog.18987.CrossRefPubMed

87.

Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2). https://doi.org/10.1161/CIRCOUTCOMES.116.003497.

88.

Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36(18):1090–7. https://doi.org/10.1093/eurheartj/ehv009.CrossRefPubMedPubMedCentral

89.

Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011;97(23):1970–81. https://doi.org/10.1136/heartjnl-2011-300349.CrossRefPubMed

90.

Skrzynia C, Berg JS, Willis MS, Jensen BC. Genetics and heart failure: a concise guide for the clinician. Curr Cardiol Rev. 2015;11(1):10–7. https://doi.org/10.2174/1573403x09666131117170446.CrossRefPubMedPubMedCentral

91.

Lee DS, Pencina MJ, Benjamin EJ, Wang TJ, Levy D, O'Donnell CJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006;355(2):138–47. https://doi.org/10.1056/NEJMoa052948.CrossRefPubMed

92.

Lopes LR, Elliott PM. Genetics of heart failure. Biochim Biophys Acta. 2013;1832(12):2451–61. https://doi.org/10.1016/j.bbadis.2012.12.012.CrossRefPubMed

93.

Yang J, Xu WW, Hu SJ. Heart failure: advanced development in genetics and epigenetics. Biomed Res Int. 2015;2015:352734–11. https://doi.org/10.1155/2015/352734.CrossRefPubMedPubMedCentral

94.

• Aung N, Vargas JD, Yang C, Cabrera CP, Warren HR, Fung K, et al. Genome-wide analysis of left ventricular image-derived phenotypes identifies fourteen loci associated with cardiac morphogenesis and heart failure development. Circulation. 2019;140(16):1318–30. https://doi.org/10.1161/CIRCULATIONAHA.119.041161. This study explores the genetic basis of left ventricular phenotypes.CrossRefPubMedPubMedCentral

95.

• Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic/Latino ancestry. JAMA. 2019;322(22):2191–202. https://doi.org/10.1001/jama.2019.17935. The investigators reported an association between the TTR V122I genetic variant and heart failure, in a selected population.CrossRefPubMedPubMedCentral

96.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128.CrossRefPubMed

97.

De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996–2004; discussion 5. https://doi.org/10.1161/CIRCULATIONAHA.110.981431.CrossRefPubMed

Title: Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction
Authors: Andrew Xanthopoulos
Apostolos Dimos
Grigorios Giamouzis
Angeliki Bourazana
Alexandros Zagouras
Michail Papamichalis
Takeshi Kitai
John Skoularigis
Filippos Triposkiadis
Publication date: 01-08-2020
Publisher: Springer US
Keyword: Heart Failure
Published in: Current Heart Failure Reports / Issue 4/2020
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-020-00461-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

Impact of Sacubitril-Valsartan on Markers of Glomerular Function

Ethical Challenges in Care of Patients on Mechanical Circulatory Support at End-of-Life

Cardiac Rehab for Functional Improvement

Contemporary Management Strategies in VAD Infection

Continuous-Flow Left Ventricular Assist Devices and the Aortic Valve: Interactions, Issues, and Surgical Therapy

Hepatitis C–Positive Donors in Cardiac Transplantation: Problems and Opportunities

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page